The $290 bln UK-based company will licence weight-loss drugs from China’s CSPC in a deal worth up to $18.5 bln. It’s the latest overseas giant drawn to the Asian country’s growing biotech prowess. But ...

A customs duty exemption on select high-cost cancer and rare disease therapies is expected to lower treatment costs for ...

Europe hedges its bets as Starmer courts China, war tech backfires in Ukraine, AstraZeneca doubles down, and Denmark asserts ...

RFK Jr. says TrumpRX will launch "probably in the next 10 days." What we know about how buying medicine, getting discounts on prescription drugs will work ...

Three U.S. senators sent a letter to the HHS Office of Inspector General raising questions about TrumpRx — whose structure ...

SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental ‌drugs ​for obesity and weight-related conditions from ...

The agreement, to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs is the largest of its ...

CSPC said earlier Friday that it entered an obesity drug agreement with AstraZeneca that would give the U.K.-based pharmaceutical company rights outside China to its clinical-ready long-acting obesity ...

Dow Jones Top Company Headlines at 3 AM ET: OpenAI Plans Fourth-Quarter IPO in Race to Beat Anthropic to Market | AstraZeneca ... OpenAI Plans Fourth-Quarter IPO in Race to Beat Anthropic to Market ...

With large pharma companies now confronting a two-pronged assault on U.S. | On Wednesday, the U.S. Chamber of Commerce filed an amicus brief calling on the Supreme Court to review a lower court ...

Fintel reports that on January 27, 2026, Citigroup initiated coverage of AstraZeneca PLC - Depositary Receipt (NasdaqGS:AZN) ...

Negotiated prices for Kisqali and Verzenio, which the agency said cost Medicare over $1 billion in a year, would become effective starting 2028.